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Objectives. This study sought to examine the effects of long-
term estrogen therapy on vascular function in male to female
transsexuals and to compare the findings with those observed in
men and premenopausal women.
Background. Gender differences in coronary artery disease
have largely been attributed to the beneficial effects of estrogen on
vascular function and plasma lipids in women. However, the
effects of estrogen on the male vasculature have not been widely
studied.
Methods. We compared the effects of estrogen on vascular
function in 14 male to female transsexuals, 14 age-matched men
and 15 premenopausal women. Flow-mediated vasodilation and
response to nitroglycerin were assessed in the brachial artery
using noninvasive ultrasound.
Results. Flow-mediated vasodilation was similar in transsexu-
als and women but greater than that in men ([mean 6 SE] 11.5 6
1.3% and 9.4 6 1.1% vs. 5.2 6 1.0% respectively, p < 0.005).
Responses to nitroglycerin were also greater in transsexuals and
women than in men (21.6 6 1.7% and 21.0 6 0.9% vs. 14.5 6 1.2%,
respectively, p 5 0.0005). These differences persisted even after
adjusting for vessel size. Despite similar total cholesterol levels,
transsexuals had high density lipoprotein cholesterol levels sim-
ilar to those in women and greater than those observed in men
(1.76 6 0.12 and 1.82 6 0.11 mmol/liter vs. 1.35 6 0.07 mmol/liter,
respectively, p < 0.005). Moreover, triglyceride levels were greater
in transsexuals than in men and women, and low density lipopro-
tein cholesterol (LDL-C) particle size was smaller (25.7 6 0.2 nm
vs. 26.2 6 0.1 and 26.6 6 0.1 nm, respectively, p 5 0.0001). Serum
testosterone (an index of estrogen therapy in transsexuals) was
markedly suppressed in transsexuals and similar to that in
women. Univariate analysis revealed that there was a strong
inverse correlation between serum testosterone and flow-mediated
vasodilation (rs 5 20.48, p < 0.005). Multivariate analysis
revealed that the best combination of predictors of flow-mediated
vasodilation was serum testosterone, vessel size and LDL-C (R2 5
0.3, p < 0.005).
Conclusions. Long-term estrogen therapy appears to improve
vascular function in male to female transsexuals and occurs
despite higher triglyceride levels and the presence of small, dense
LDL-C. The beneficial effects of estrogen are not gender specific or
solely mediated through endothelium-derived nitric oxide.
(J Am Coll Cardiol 1997;29:1437–44)
©1997 by the American College of Cardiology
Gender differences in coronary artery disease (CAD) have
been known for many years (1). The differential risk of CAD
between men and premenopausal women has largely been
explained in terms of the beneficial effects of endogenous
estrogen and is supported by the fact that postmenopausal
women taking hormone replacement therapy (HRT) appear to
have a significantly lower risk of CAD than their untreated
counterparts. This benefit is possibly even greater in women
with proven CAD (2).
The mechanisms by which estrogen exerts its cardioprotec-
tive effects are probably multifactorial. The benefits may in
part be due to favorable alterations in the lipid profile. Studies
in postmenopausal women have shown that estrogen replace-
ment therapy reduces low density lipoprotein cholesterol
(LDL-C) and raises high density lipoprotein cholesterol
(HDL-C). However, only a fraction of the beneficial effects can
be explained by these changes (3). Another postulated mech-
anism is that estrogen exerts a direct effect on the vascular
endothelium and smooth muscle. Several workers have shown
(4,5) that short-term administration of estrogen in postmeno-
pausal women improves endothelium-dependent vasodilation
in both the coronary and peripheral circulations. Estrogen may
also alter basal blood flow in these beds (4). Although the
mechanism is unclear, experimental studies (6) suggest that the
improvement in vasodilator effects of estrogen may be partly
mediated through the L-arginine–nitric oxide (NO) pathway.
The effects of estrogens in men are less clear. Early studies
suggested that men prescribed high dose estrogen had an
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increased cardiovascular morbidity and mortality (7,8). How-
ever, low to moderate doses appear to have a beneficial effect
on mortality (9,10). Interestingly, both clinical and experimen-
tal studies (7,11,12) indicate that estrogen has a favorable
effect on plasma lipoproteins in men similar to that observed in
postmenopausal women taking HRT.
The long-term effects of estrogen on vascular function in
men has not been studied in detail. Long-term studies of
estrogen in men are logistically difficult, except in specific
populations, such as male to female transsexuals or men with
prostatic cancer. However, studies in the latter group are often
compounded by advancing age and the presence of comorbid
illnesses. Male to female transsexuals, prescribed estrogen for
the purpose of feminization, provide a unique opportunity to
study the long-term effects of estrogen on the male vasculature.
Therefore, the aim of the present study was to examine the
effects of long-term estrogen therapy on vascular function in
male to female transsexuals and to compare the findings with
those observed in men and premenopausal women.
Methods
Subjects. Fourteen male to female transsexuals, 14 age-
matched healthy men and 15 age-matched healthy premeno-
pausal women between 21 and 57 years old were recruited
(Table 1). Subjects were enrolled from October 31, 1995 to
October 10, 1996. The transsexuals were recruited from the
Gender Dysphoria Clinic of the Department of Psychological
Medicine at Monash Medical Centre. The transsexuals had
been taking estrogen (ethinyl estradiol [10] or conjugated
equine estrogen—Premarin [4]) for at least 5 months (61 6 70
months, mean 6 SD). The doses prescribed were approxi-
mately two to three times the conventional oral contraceptive
and comparable to high dose HRT. The mean oral dose of
ethinyl estradiol was 118 6 60 mg, and the mean oral dose of
Premarin was 1.03 6 0.35 mg. The doses of estrogen pre-
scribed were sufficient to produce “medical orchidectomy,”
thereby reducing serum testosterone levels to within the
normal female range. Three transsexuals had also undergone
surgical orchidectomy as part of their gender reassignment
program; 11 transsexuals were taking spironolactone; and 2
were also taking cyproterone acetate for hirsutism. One trans-
sexual had multiple coronary risk factors (hypercholesterol-
emia, non–insulin-dependent diabetes mellitus and a family
history of CAD); one had a family history of CAD; and
another had hypercholesterolemia with a LDL-C level of 4.5
mmol/liter. Three other transsexuals were smokers.
The men and women were recruited by advertisement.
Male control subjects had never taken estrogen, spironolac-
tone or cyproterone acetate or undergone orchidectomy or had
a history of infertility. All had serum testosterone levels within
the normal male range. Female control subjects were pre-
menopausal, had regular menses, were not taking hormonal
contraception and were studied during the follicular or luteal
phase of their menstrual cycle to maximize the effects of
estrogen, as described in previous studies (13). Control sub-
jects were excluded if they had any coronary risk factors,
including a total cholesterol or LDL-C level greater than the
75th percentile for their age and gender based on the Risk
Factor Prevalence Study (14). All subjects gave written in-
formed consent. The study was approved by the Human
Research and Ethics Committee of Monash Medical Centre,
and all procedures followed were in accordance with institu-
tional guidelines.
Study design. All subjects were screened with a medical
history, examination and electrocardiogram (ECG). Blood
samples were taken after a 10-h overnight fast to measure
plasma concentrations of lipids, glucose and serum concentra-
tions of testosterone and estradiol in women. All specimens
were measured within 48 h of blood sampling. Total choles-
terol, HDL-C and triglyceride (TG) concentrations were mea-
sured enzymatically. LDL-C was calculated according to the
Friedewald formula. If the TG levels were .4.5 mmol/liter,
LDL-C was not calculated. LDL-C particle size was measured
using 3% to 13% gradient gel electrophoresis (Gradipore, New
South Wales, Australia). Serum testosterone levels were used
as an index of estrogen therapy in the transsexuals and were
measured by radioimmunoassay. Serum estradiol levels were
not measured in the transsexual group because ethinyl estra-
diol and conjugated equine estrogen (the agents used by the
transsexuals for feminization) have low cross reactivity with the
radioimmunoassay for estradiol.
Abbreviations and Acronyms
CAD 5 coronary artery disease
ECG 5 electrocardiogram, electrocardiographic
FMD 5 flow-mediated vasodilation
GTN 5 nitroglycerin
HDL-C 5 high density lipoprotein cholesterol
HRT 5 hormone replacement therapy
LDL-C 5 low density lipoprotein cholesterol
NO 5 nitric oxide
NOS 5 nitric oxide synthase
TG 5 triglycerides
Table 1. Baseline Characteristics
TX
(n 5 14)
(mean 6 SD)
Men
(n 5 14)
(mean 6 SD)
Women
(n 5 15)
(mean 6 SD)
Age (yr) 41 6 9 41 6 7 40 6 8
BMI (kg/m2) 23 6 3 25 6 4 24 6 5
W/H 0.86 6 0.07 0.87 6 0.05 0.76 6 0.06*
SBP (mm Hg) 126 6 15 123 6 9 116 6 12
DBP (mm Hg) 75 6 11 74 6 5 71 6 11
No. of CRFs 0.57 6 0.85† 0 0
Testosterone (nmol/liter) 1.8 6 1.3 17.2 6 5.4* 1.9 6 0.5
*p 5 0.0001. †p , 0.005. BMI 5 body mass index; CRFs 5 coronary risk
factors; DBP 5 diastolic blood pressure; SBP 5 systolic blood pressure; W/H 5
waist/hip ratio; TX 5 transsexuals.
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Brachial artery ultrasound. Brachial ultrasound studies
were performed in the morning in a quiet, temperature-
controlled laboratory. Blood pressure was monitored in the left
arm at 2-min intervals by an automated blood pressure re-
corder (Critikon, Dinamap 845 XT BP monitor). ECG leads
were attached to the ultrasound recorder for on-line continu-
ous heart rate monitoring. The ultrasound studies were con-
ducted by the same examiner throughout the study. All pa-
tients rested in the supine position for at least 10 min before
the study. Studies of the right brachial artery were performed
using a high resolution ultrasound machine (ATL, HDI Ultra-
mark 9) with a 7- to 10-MHz linear array transducer. Longi-
tudinal images of the brachial artery were obtained proximal to
the antecubital fossa wherever the best ultrasound image could
be obtained. Operating variables of the machine were kept
constant during each study. Transmit focus zones were set
approximately to the depths of the anterior and posterior
vessel walls. Images were magnified, whereas depth and gain
settings were set to optimize the image of the vessel wall, in
particular, the media–adventitia interface (“m” line), as previ-
ously described (15). When an adequate transducer position
was obtained, the skin was marked and the arm kept in a
constant position throughout the study. A still photograph of
the baseline image in addition to anatomic markers, such as
side branches, were used to aid the examiner in maintaining a
constant transducer position throughout the study.
The technique for assessing endothelium-dependent and
-independent vasodilation has been described in detail else-
where (15). In short, we assessed flow-mediated, endothelium-
dependent vasodilation by measuring the arterial diameter of
the brachial artery before and during reactive hyperemia
(induced after deflation of a blood pressure cuff previously
inflated to suprasystolic pressure for 5 min). We then assessed
endothelium-independent vasodilation in response to sublin-
gual nitroglycerin (GTN). Arterial flow velocity was measured
with a pulsed Doppler signal at a 70° angle to the vessel with
the range gate (1.5 mm) in the center of the vessel. The
flow-mediated vasodilator response to reactive hyperemia was
then continuously recorded (from 30 s before cuff deflation
and until 5 min after deflation). Arterial flow velocity was also
assessed 15 s after the cuff was released. Rest baseline diam-
eter and flow were then reassessed 20 min later. Nitroglycerin
(0.4 mg) was then administered sublingually, and the brachial
artery image was recorded for 5 min to measure maximal
vasodilation. Arterial flow velocity was again measured at
2 min 30 s.
Data analysis. Maximal arterial diameter after reactive
hyperemia was assessed 45 to 90 s after cuff deflation and 3 to
5 min after GTN administration, in accordance with previously
described methods (15). The ultrasound images were recorded
on Super-VHS videotape for subsequent analysis. Images were
digitized using a frame grabber (Scion LG-3) and then stored
on a Macintosh computer (Centris 650). All images were
grabbed on the R wave (end-diastole) of the continuous ECG
recording. Subsequent analysis was performed on the same
computer using a modified version of the public domain NIH
Image Program, originally developed at the U.S. National
Institutes of Health. The diameter of the vessel was measured
by two investigators (K.L.J., B.T.T.) who had no knowledge the
scan sequence and gender of the subjects. Arterial diameter
was measured from a fixed anatomic marker in all scans of the
same patient. Arterial diameter was measured from the ante-
rior “m” line (media–adventitia interface) to the media–lumen
interface on the posterior wall. Approximately 20-mm straight
segments of the artery were measured automatically, and the
average diameter was calculated. Two comparable and repre-
sentative frames were analyzed. Each frame was measured
three times, and all six measurements were then averaged. The
percent change in the brachial artery diameter was then
calculated in response to reactive hyperemia (flow-mediated
vasodilation [FMD]) and GTN. FMD was also adjusted for
vessel size (by dividing by baseline diameter) because previous
studies (15,16) have shown a strong negative correlation
between vessel diameter and FMD (r 5 20.81) and GTN (r 5
20.80). If there were .3% discrepancy between the two
investigators’ results, the diameters were remeasured. Blood
flow was calculated by multiplying the velocity–time integral of
the Doppler flow signal by heart rate and the cross-sectional
area of the vessel. Flow velocity was measured from the center
of the vessel, which may overestimate absolute values; how-
ever, relative values before and after cuff inflation are accurate
(15). Hyperemia (percent increase in flow) was calculated by
subtracting the maximal flow recorded ;15 s after cuff defla-
tion from the baseline flow divided by the baseline flow (%
Hyperemia 5 [{Fp 2 Fb}/Fbp100], where Fp 5 peak flow; and
Fb 5 baseline flow).
Statistical analysis. Descriptive data are expressed as mean
value 6 SD and results as mean value 6 SE. Statistical signifi-
cance was taken as p , 0.05. Between-group comparisons were
made using one-way analysis of variance with Bonferroni correc-
tion for multiple comparisons. Logarithmic transformation of
serum testosterone and triglycerides were used in the analysis of
variance. Univariate analysis using a Spearman rank correlation
was used to determine the relation between the dependent
variables (responses to FMD and GTN) and independent vari-
ables (age, vessel size, body mass index, waist/hip ratio, total
cholesterol, HDL-C, LDL-C, LDL-C particle size, TG, testoster-
one and systolic and diastolic blood pressures). Multivariate
analysis was performed using multiple linear regression to deter-
mine the best combination of predictor variables.
Results
The clinical and morphometric characteristics of the sub-
jects are described in Table 1. There were no significant
differences in age, body mass index or systolic and diastolic
blood pressures. Waist/hip ratio was less in women than in
transsexuals and men ([mean 6 SD] 0.76 6 0.06 vs. 0.85 6 0.07
and 0.88 6 0.05, respectively, p 5 0.0001). The average
number of risk factors was greater in transsexuals than in the
men and women (p , 0.005, for transsexuals vs. men and
women). Serum testosterone levels were similar in transsexuals
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and women but lower than those observed in men (1.8 6 1.3
and 1.9 6 0.5 nmol/liter vs. 17.2 6 5.4 nmol/liter, respectively,
p 5 0.0001 for transsexuals and women vs. men).
Flow-mediated vasodilation. The percent change in bra-
chial arterial diameter after reactive hyperemia was similar in
transsexuals and women but greater than that observed in men
([mean 6 SE] 11.5 6 1.3% and 9.4 6 1.1% vs. 5.2 6 1.0%,
respectively, p , 0.005 for transsexuals and women vs. men)
(Fig. 1, Table 2). Baseline brachial artery diameter was similar
in transsexuals and women but less than that observed in men
(4.0 6 0.1 and 3.6 6 0.1 mm vs. 4.9 6 0.2 mm, respectively, p 5
0.0001 for transsexuals and women vs. men). After adjusting
responses for brachial artery diameter, FMD remained similar
in transsexuals and women but greater than that in men (2.9 6
0.4% and 2.7 6 0.4% vs. 1.2 6 0.3%, respectively, p 5 0.001 for
transsexuals and women vs. men) (Table 2).
Rest blood flow was similar in transsexuals and men but
greater than that in women (134 6 14 and 161 6 21 ml/min vs.
90 6 8 ml/min, respectively, p , 0.01 for men vs. women).
There was no difference in hyperemic flow between the three
groups.
GTN-induced vasodilation. Vasodilation in response to
sublingual GTN was 33% greater in transsexuals and women
than men (21.6 6 1.7% and 21.0 6 0.9% vs. 14.5 6 1.2%,
respectively, p 5 0.0005 for transsexuals and women vs. men)
(Fig. 2, Table 2). Similarly, after adjustment for brachial artery
diameter, GTN-induced vasodilation remained greater in
transsexuals and women than in men (5.5 6 0.6% and 6.0 6
0.4% vs. 3.1 6 0.4%, respectively, p 5 0.0001 for transsexuals
and women vs. men) (Table 2).
Lipid profiles. Total cholesterol levels were similar in all
groups ([mean 6 SE] 5.5 6 0.4, 5.1 6 0.2 and 5.0 6 0.1
mmol/liter for transsexuals, men and women, respectively)
(Table 3). HDL-C levels were also similar in transsexuals and
women and approximately 23% higher than that observed in
men (1.76 6 0.12 and 1.82 6 0.11 mmol/liter vs. 1.35 6 0.07
mmol/liter, respectively, p , 0.005 for transsexuals and women
vs. men). Plasma LDL-C levels were similar in transsexuals and
women, but lower than those observed in men (2.6 6 0.3 and
2.8 6 0.2 mmol/liter vs. 3.3 6 0.2 mmol/liter, respectively, p ,
0.05 for transsexuals vs. men). TG levels were substantially
higher in transsexuals than in women and men (2.3 6 0.4
mmol/liter vs. 0.8 6 0.1 and 0.9 6 0.1 mmol/liter, respectively,
p 5 0.0001 for transsexuals vs. women and men). LDL-C
particle size was smaller in transsexuals than in women and
Figure 1. Flow-mediated vasodilation in male to female transsexuals
(TX), men (M) and premenopausal women (F). Horizontal lines 5
group mean values; circles 5 individual subjects.
Table 2. Vascular Variables
TX
(n 5 14)
(mean 6 SE)
Men
(n 5 14)
(mean 6 SE)
Women
(n 5 15)
(mean 6 SE)
FMD (%) 11.5 6 1.3 5.2 6 1.0* 9.4 6 1.1
Baseline vessel size (mm) 4.1 6 0.1 4.9 6 0.2† 3.6 6 0.2
aFMD (%/mm) 2.9 6 0.4 1.2 6 0.3‡ 2.7 6 0.4
Baseline flow (ml/min) 134 6 14 161 6 21 90 6 8§
Hyperemia (% inc
in flow)
687 6 113 564 6 90 740 6 103
GTN (%) 21.6 6 1.7 14.5 6 1.2\ 21.0 6 0.9
aGTN (%/mm) 5.5 6 0.6 3.1 6 0.4† 6.0 6 0.4
*p , 0.005. †p 5 0.0001. ‡p , 0.001. §p , 0.01. \p 5 0.0005. aFMD 5
flow-mediated dilation adjusted for vessel size (percent flow-mediated vasodila-
tion divided by baseline diameter [mm]); aGTN 5 nitroglycerin-induced vaso-
dilation adjusted for vessel size (percent nitroglycerin-induced vasodilation
divided by baseline diameter [mm]); FMD 5 flow-mediated vasodilation;
GTN 5 nitroglycerin-induced vasodilation; inc 5 increase; TX 5 transsexuals.
Table 3. Lipid Profiles
TX
(n 5 14)
(mean 6 SE)
Men
(n 5 14)
(mean 6 SE)
Women
(n 5 15)
(mean 6 SE)
TC (mmol/liter) 5.5 6 0.4 5.1 6 0.2 5.0 6 0.1
HDL-C (mmol/liter) 1.76 6 0.12 1.35 6 0.07* 1.82 6 0.11
LDL-C (mmol/liter) 2.6 6 0.3 3.3 6 0.2† 2.9 6 0.2
TG (mmol/liter) 2.3 6 0.4‡ 0.9 6 0.1 0.8 6 0.1
LDL-C particle size (nm) 25.7 6 0.2‡ 26.2 6 0.1 26.6 6 0.1
*p , 0.01. †p , 0.05. ‡p 5 0.0001. HDL-C 5 high density lipoprotein
cholesterol; LDL-C 5 low density lipoprotein cholesterol; TC 5 total choles-
terol; TG 5 triglycerides; TX 5 transsexuals.
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men (25.7 6 0.2 nm vs. 26.6 6 0.1 and 26.2 6 0.1 nm,
respectively, p 5 0.0001 for transsexuals vs. women and men).
Regression analysis. Univariate analysis revealed that the
best single predictor of FMD was serum testosterone—our
index of estrogen therapy (rs 5 20.48, p , 0.005). Other
predictors were HDL-C (rs 5 0.42, p , 0.01) (Fig. 3), vessel
size (rs 5 20.38, p , 0.01), waist/hip ratio (rs 5 20.36, p ,
0.02) and LDL-C (rs 5 20.34, p , 0.05) (Fig. 4). Multiple
regression analysis revealed that the best combination of
predictors of FMD was serum testosterone, vessel size and
LDL-C (R2 5 0.3, p , 0.005).
With respect to GTN-mediated vasodilation, univariate
analysis revealed the best single predictor to be vessel size
(rs 5 20.46, p , 0.001). Other predictors were serum testos-
terone (rs 5 20.43, p , 0.01) and waist/hip ratio (rs 5 20.31,
p , 0.05). On multivariate analysis, the best combination of
predictors of response to GTN was vessel size, serum testos-
terone and LDL-C (R2 5 0.36, p , 0.001).
The magnitude of the FMD and GTN responses in the
transsexual group did not correlate with duration, dose or
formulation of estrogen therapy. Moreover, FMD and GTN
responses were not related to the presence of coronary risk
factors, use of spironolactone or gender reassignment surgery
in the transsexual group.
Discussion
Previous studies in women have demonstrated (13,17,18)
that estrogen appears to improve endothelium-dependent as
Figure 2. Nitroglycerin-induced vasodilation in male to female trans-
sexuals (TX), men (M) and premenopausal women (F). Symbols as in
Figure 1.
Figure 3. Relation between FMD and HDL-C in all groups (rs 5 0.42,
p , 0.01). Diagonal line 5 linear relation; circles 5 individual subjects.
Figure 4. Relation between FMD and LDL-C in all groups (rs 5
20.34, p , 0.05). Symbols as in Figure 3.
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well as -independent vasodilation. To our knowledge, this
study is the first to report that long-term estrogen therapy
enhances vascular function in men. This finding indicates that
the effects of long-term estrogen therapy on the vasculature
are not gender specific. Moreover, because we demonstrated
both endothelium-dependent and -independent effects of es-
trogen, the improvement in vasodilation cannot be solely
attributed to endothelium-dependent NO-mediated mecha-
nisms.
Using a well validated, noninvasive ultrasound technique,
we demonstrated that long-term administration of estrogen
can enhance endothelium-dependent and -independent vaso-
dilation in the conduit arteries of men. Specifically, we were
able to show that both flow-mediated vasodilation, a process
known to be largely NO dependent in humans (19), and
GTN-induced vasodilation are enhanced in male to female
transsexuals compared with age-matched men. The vascular
responses in the transsexuals are strikingly similar to those
observed in age-matched premenopausal women.
The observation that estrogen improved both endothelium-
dependent and -independent vasodilation is consistent with the
findings of Hashimoto et al. (13). They observed an increase in
both endothelium-dependent and -independent vasodilation in
women during the follicular and luteal phases of their men-
strual cycle (when serum estrogen levels are high) (13).
However, Lieberman et al. (5) found that estrogen replace-
ment therapy improved endothelium-dependent vasodilation
only. More recent studies (20–22) suggest that the effects of
estrogen are unlikely to be solely mediated through
endothelium-dependent NO.
Effects on endothelium-dependent vasodilation. The mecha-
nisms underlying estrogen’s capacity to improve vascular func-
tion in men were not examined in the present study. Several
experimental and clinical studies in women (6,17) have pro-
posed that estrogen enhances endothelium-dependent NO-
mediated vasodilation. How this might occur remains unclear.
The possibilities include 1) an alteration in receptor or postre-
ceptor signaling; 2) augmentation of endothelial NO synthesis;
or 3) a reduction in NO sequestration by oxygen-derived free
radicals. Studies by Weiner et al. (23) in a pig model suggest
that estrogen does indeed augment NO synthase (NOS) activ-
ity. Interestingly, Weiner et al. also found that estrogen
induced calcium-dependent NOS activity in both female and
male tissues, although a longer duration of treatment was
necessary to induce NOS in male tissue. The delay in response
in male tissue presumably is due to the need for estrogen
receptor priming.
Estrogen may also enhance endothelium-dependent vaso-
dilation by preventing NO sequestration by oxygen-derived
free radicals. NO readily combines with such oxygen-derived
free radicals, which results in a loss of its biologic activity.
Estrogen may act to directly inhibit or scavenge such oxygen-
derived free radicals, thereby preserving released NO. The
beneficial effects of estrogen in preserving and restoring
endothelium-dependent vasodilation in experimental models
of hypercholesterolemia may in part be explained by a free
radical scavenging effect (24).
Effects on endothelium-independent vasodilation. As al-
luded to earlier, the augmented GTN-induced vasodilation
observed in transsexuals in the present study indicates that the
effect of estrogen on vascular function is not solely confined to
an endothelium-dependent NO-mediated mechanism. Aug-
mented GTN-induced vasodilation with estrogen has been
observed in other studies (in women) (13,18) and may reflect
an increased responsiveness of the NO–guanylate cyclase
pathway at the level of the smooth muscle cell. Alternatively,
the effects of estrogen may be through other pathways that
regulate vascular smooth muscle tone (20–22). Modification of
other intrinsic vasodilator pathways or inhibition of the pre-
vailing vasoconstrictor forces may be involved. A recent study
(20) using explanted precontracted coronary arteries, demon-
strated estradiol-induced coronary relaxation with and without
intact endothelium and after NO and prostaglandin inhibition.
Estrogen has also been shown to have calcium antagonistic
properties in the coronary arteries (22) and to inhibit endothelin-
1–induced vasoconstriction through inhibition of calcium in-
flux (25). Moreover Polderman et al. (26) have shown that
estrogen therapy reduces endothelin-1 levels in transsexuals.
Estrogen increases potassium conductance in vascular smooth
muscle, a shift that may favour vasodilation (27). In addition,
estrogen can modulate adrenergic responses in many vascular
beds; however, the specificity of its effect on endothelium or
smooth muscle cells has not yet been established (28).
As has previously been argued, distinctions should also be
made between the mechanisms underlying the short- and
long-term effects of estrogen. Although we observed that
vascular function is enhanced in men receiving long-term
estrogen therapy, recent reports on the short-term effects of
estrogen on the male vasculature are contradictory. Blumen-
thal et al. (29) found that intracoronary Premarin enhanced
the endothelial-dependent vasodilator response in men with
mildly atheromatous coronary arteries. However, Collins et al.
(30) were unable to demonstrate augmented endothelium-
dependent vasodilation after intracoronary 17-beta-estradiol in
a similar group of men. Our data, indicating a beneficial effect
of long-term estrogen therapy, may reflect the need for estro-
gen receptor priming or other longer term genomic responses.
Effects on lipoproteins. In the present study we observed
that transsexuals prescribed estrogen therapy had a 23%
higher HDL-C level and an 23% lower LDL-C level than
age-matched men. Although the HDL-C and LDL-C levels
were comparable with those observed in women, transsexuals
had a substantially higher TG level and smaller LDL particle
size. Similar changes in lipid profiles have been reported
(12,31) in transsexuals prescribed Premarin (both with and
without castration) and in men treated with estrogen for
prostate cancer.
Previous studies have shown (32) that various lipid subfrac-
tions are important determinants of the integrity of vascular
endothelium. Furthermore, aggressive modification of plasma
lipids can improve endothelial vasodilator function in humans
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(33). One interesting finding of our study was that vascular
function was enhanced in transsexuals despite the presence of
smaller, dense LDL-C particles. Small dense LDL-C has been
found to be associated with premature CAD in humans (34).
The finding that vascular function was enhanced in the pres-
ence of smaller LDL-C particles suggests that estrogen acts
through more complex mechanisms than lipid profile modifi-
cations alone.
Effects on male vasculature. There is a paucity of studies
examining the effects of estrogen on cardiovascular disease in
men. Some studies (9,10) have suggested that low dose estro-
gen reduces cardiovascular morbidity and mortality in men
after myocardial infarction. Others have reported (7,8,35) an
increased incidence of cardiovascular events, particularly for
higher doses of estrogen. These findings have led to the view
that estrogen may have a deleterious effect on the male
vasculature. Not surprisingly, there are few recent studies and
limited data on the long-term effects of estrogen in adult men.
Most data have been derived from studies of men with prostate
cancer receiving estrogen for the purpose of androgen sup-
pression. Interpretation of the findings from this cohort is
often confounded by advanced age, comorbid illness and the
presence of established coronary heart disease. Male to female
transsexuals therefore provide a valuable insight into the
long-term effects of estrogen therapy in men. Our study cohort
was relatively young (mean age 41 years) and by and large free
of coronary risk factors or established vascular disease.
Limitations of the study. An important limitation of the
present study is that it is a cross-sectional comparison of a
small number of subjects and does not provide an insight into
the vascular function in the transsexual group before com-
mencing estrogen therapy. However, longitudinal studies are
difficult because male to female transsexuals invariably com-
mence estrogen therapy before their presentation to a gender
dysphoria clinic.
Another limitation of our study was the lack of direct and
quantitative measurement of ethinyl estradiol and Premarin.
These forms of estrogen do not completely cross react with the
antibodies in the available radioimmunoassays for estradiol.
We therefore relied on the suppression of serum testosterone,
which is conventionally used as an index of estrogen therapy in
male to female transsexuals.
We were also unable to determine whether the improve-
ment in vascular function in transsexuals is due to estrogen
itself or to the relative testosterone deficiency created by
estrogen therapy and other forms of androgen suppression
used in these subjects. It is possible but as yet unresolved that
the improvement in vascular function is due to androgen
suppression. A recent abstract by Herman et al. (36) is
consistent with this hypothesis. However, several recent studies
have demonstrated (37–39) that the short-term administration
of testosterone improves both endothelium-dependent and
-independent vasodilation in the coronary and forearm circu-
lations that is gender independent. Studies in hypogonadal
men before and after treatment will ultimately provide an
important insight into this question.
Conclusions. Gender differences in CAD have tradition-
ally been attributed to the beneficial effects of estrogen on
plasma lipids and vascular function in women. Whether this
benefit can be conferred on the male population is unclear. We
therefore studied the effects of long-term estrogen therapy on
vascular function in male to female transsexuals—a cohort that
provides a unparalleled insight into the effects of the female
sex hormones on male vasculature. We found that the benefi-
cial effects of estrogen are not gender specific or solely
mediated through NO-mediated mechanisms. Improved vas-
cular function in men taking estrogen may in part be explained
through alterations in the lipid profile, but other factors are
likely to be involved.
Clearly, more studies into the short- and long-term effects
of estrogen in men are required, in particular, studies into the
mechanisms by which estrogen may exert its effects.
We gratefully acknowledge the tireless assistance of Karen L. Berry BSc(Hons),
Annette M. Bond, BA and Anthony N. Hunter, MBBS.
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